Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | PTGFR | P43088 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.45 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31298063 | 0.89 | MEN1 (0.67) | MEN1KMT2AHIF1AHSD11B1KDM4E | |
| SCHEMBL12835154 | 0.88 | MEN1 (0.67) | MEN1KMT2AHIF1AHSD11B1KDM4E | |
| SCHEMBL16359225 | 0.86 | KMT2A (0.65) | MEN1KMT2AHIF1AHSD11B1KDM4E | |
| SCHEMBL95518 | 0.86 | KMT2A (0.65) | MEN1KMT2AHIF1AHSD11B1KDM4E | |
| SCHEMBL12459940 | 0.86 | NPC1 (0.49) | MEN1KMT2APARP1RAB9ANPC1 | |
| SCHEMBL17886691 | 0.84 | MEN1 (0.66) | MEN1KMT2AHIF1AHSD11B1KDM4E | |
| SCHEMBL11628586 | 0.83 | KMT2A (0.71) | MEN1KMT2AHIF1AHSD11B1KDM4E | |
| SCHEMBL16105732 | 0.81 | KMT2A (0.59) | MEN1KMT2AHIF1AHSD11B1KDM4E | |
| SCHEMBL2755865 | 0.81 | KDM4E (0.62) | MEN1KMT2AHIF1AHSD11B1KDM4E | |
| SCHEMBL4703240 | 0.80 | MEN1 (0.58) | MEN1KMT2AHIF1AHSD11B1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928879-B1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-02-13 | — | — | EP | disclosed |
| EP-2298304-A2 | Carboline derivatives useful in the treatment of cancer | PTC Therapeutics, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-12 | — | — | US | disclosed |
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-12 | — | — | US | disclosed |
| US-7741318-B2 | Pyrazolo [1,5-A]pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741318-B2 | Pyrazolo [1,5-A]pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741318-B2 | Pyrazolo [1,5-A]pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2010-06-22 | — | — | US | disclosed |
| US-7723336-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723336-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-25 | — | — | US | disclosed |
| EP-1836205-B1 | PYRAZOLO[1,5-A]PYRIMIDINE ADENOSINE A2a RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-1836205-B1 | PYRAZOLO[1,5-A]PYRIMIDINE ADENOSINE A2a RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008127714-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20070078136-A1 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| WO-2007038314-A2 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070078136-A1 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| US-20060135526-A1 | Pyrazolo [1,5-A] pyrimidine adenosine A2a receptor antagonists | MERCK SHARP & DOHME LLC | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078136-A1 | Fused heterocyclic compounds useful as kinase modulators | MAP3K2, MAP3K3, MAP4K2 | MEN1 1569/4885KMT2A 665/4885HIF1A 3637/4885 |
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | MAP2K2, MAP3K2, MAP4K2 | MEN1 1665/4885KMT2A 584/4885HIF1A 3739/4885 |
| US-20060135526-A1 | Pyrazolo [1,5-A] pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA2B | MEN1 4653/4885KMT2A 3595/4885HIF1A 2749/4885 |
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | MAP3K3, MAP3K2, MAP4K3 | MEN1 1632/4885KMT2A 726/4885HIF1A 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.